James Stewart, , , Ruoqing Jia, , , Md Ackas Ali, , , Blaise Williams, , , Kaylee Stone, , , Ryan Faddis, , , Md. Shahadat Hossain, , , Andrew C. McShan, , , Mohammed Akhter Hossain, , and , Mohammad A. Halim*,
{"title":"结构导向的Temporin L类似物抑制SARS-CoV-2主要蛋白酶","authors":"James Stewart, , , Ruoqing Jia, , , Md Ackas Ali, , , Blaise Williams, , , Kaylee Stone, , , Ryan Faddis, , , Md. Shahadat Hossain, , , Andrew C. McShan, , , Mohammed Akhter Hossain, , and , Mohammad A. Halim*, ","doi":"10.1021/acsmedchemlett.5c00370","DOIUrl":null,"url":null,"abstract":"<p >Peptide-based inhibitors exhibit considerable potential as antiviral agents targeting SARS-CoV-2. In this study, we designed analogs (TLP-1, TLP-2, and TLP-3) of Temporin L (TL) peptide with the specific objective of selectively interacting with and targeting the main protease (Mpro) of SARS-CoV-2. The synthesis and characterization of TLPs were employed using solid-phase peptide synthesis and LC-MS respectively. CD and solution NMR spectroscopy elucidated the overall structure of the TLPs relative to TL, revealing folded peptides where introduced mutations alter the peptide conformation for binding to Mpro. MD simulations highlighted improvements in TLP’s stability and interactions with Mpro. FRET based protease activity assays provided evidence that TLPs exhibited enhanced inhibitory activity against Mpro. The results of our study reveal the promising prospects of TLPs as attractive candidates for <i>in vivo</i> investigations, thereby contributing to the progress of peptide-based therapeutic approaches targeting SARS-CoV-2.</p>","PeriodicalId":20,"journal":{"name":"ACS Medicinal Chemistry Letters","volume":"16 10","pages":"1963–1970"},"PeriodicalIF":4.0000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5c00370","citationCount":"0","resultStr":"{\"title\":\"Structure-Guided Temporin L Analogs Development to Inhibit the Main Protease of SARS-CoV-2\",\"authors\":\"James Stewart, , , Ruoqing Jia, , , Md Ackas Ali, , , Blaise Williams, , , Kaylee Stone, , , Ryan Faddis, , , Md. Shahadat Hossain, , , Andrew C. McShan, , , Mohammed Akhter Hossain, , and , Mohammad A. Halim*, \",\"doi\":\"10.1021/acsmedchemlett.5c00370\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >Peptide-based inhibitors exhibit considerable potential as antiviral agents targeting SARS-CoV-2. In this study, we designed analogs (TLP-1, TLP-2, and TLP-3) of Temporin L (TL) peptide with the specific objective of selectively interacting with and targeting the main protease (Mpro) of SARS-CoV-2. The synthesis and characterization of TLPs were employed using solid-phase peptide synthesis and LC-MS respectively. CD and solution NMR spectroscopy elucidated the overall structure of the TLPs relative to TL, revealing folded peptides where introduced mutations alter the peptide conformation for binding to Mpro. MD simulations highlighted improvements in TLP’s stability and interactions with Mpro. FRET based protease activity assays provided evidence that TLPs exhibited enhanced inhibitory activity against Mpro. The results of our study reveal the promising prospects of TLPs as attractive candidates for <i>in vivo</i> investigations, thereby contributing to the progress of peptide-based therapeutic approaches targeting SARS-CoV-2.</p>\",\"PeriodicalId\":20,\"journal\":{\"name\":\"ACS Medicinal Chemistry Letters\",\"volume\":\"16 10\",\"pages\":\"1963–1970\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.5c00370\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Medicinal Chemistry Letters\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00370\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Medicinal Chemistry Letters","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsmedchemlett.5c00370","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
摘要
基于肽的抑制剂作为靶向SARS-CoV-2的抗病毒药物具有相当大的潜力。在本研究中,我们设计了Temporin L (tlp)肽的类似物TLP-1、TLP-2和TLP-3,其特异性目的是选择性地与SARS-CoV-2的主要蛋白酶(Mpro)相互作用。TLPs的合成和表征分别采用固相肽合成和LC-MS。CD和溶液核磁共振光谱揭示了TLPs相对于TL的整体结构,揭示了引入突变改变肽与Mpro结合构象的折叠肽。MD模拟强调了张力腿腿的稳定性和与Mpro的相互作用的改善。基于FRET的蛋白酶活性测定提供了证据,证明TLPs对Mpro具有增强的抑制活性。我们的研究结果揭示了TLPs作为有吸引力的体内研究候选者的前景,从而促进了针对SARS-CoV-2的基于肽的治疗方法的进展。
Structure-Guided Temporin L Analogs Development to Inhibit the Main Protease of SARS-CoV-2
Peptide-based inhibitors exhibit considerable potential as antiviral agents targeting SARS-CoV-2. In this study, we designed analogs (TLP-1, TLP-2, and TLP-3) of Temporin L (TL) peptide with the specific objective of selectively interacting with and targeting the main protease (Mpro) of SARS-CoV-2. The synthesis and characterization of TLPs were employed using solid-phase peptide synthesis and LC-MS respectively. CD and solution NMR spectroscopy elucidated the overall structure of the TLPs relative to TL, revealing folded peptides where introduced mutations alter the peptide conformation for binding to Mpro. MD simulations highlighted improvements in TLP’s stability and interactions with Mpro. FRET based protease activity assays provided evidence that TLPs exhibited enhanced inhibitory activity against Mpro. The results of our study reveal the promising prospects of TLPs as attractive candidates for in vivo investigations, thereby contributing to the progress of peptide-based therapeutic approaches targeting SARS-CoV-2.
期刊介绍:
ACS Medicinal Chemistry Letters is interested in receiving manuscripts that discuss various aspects of medicinal chemistry. The journal will publish studies that pertain to a broad range of subject matter, including compound design and optimization, biological evaluation, drug delivery, imaging agents, and pharmacology of both small and large bioactive molecules. Specific areas include but are not limited to:
Identification, synthesis, and optimization of lead biologically active molecules and drugs (small molecules and biologics)
Biological characterization of new molecular entities in the context of drug discovery
Computational, cheminformatics, and structural studies for the identification or SAR analysis of bioactive molecules, ligands and their targets, etc.
Novel and improved methodologies, including radiation biochemistry, with broad application to medicinal chemistry
Discovery technologies for biologically active molecules from both synthetic and natural (plant and other) sources
Pharmacokinetic/pharmacodynamic studies that address mechanisms underlying drug disposition and response
Pharmacogenetic and pharmacogenomic studies used to enhance drug design and the translation of medicinal chemistry into the clinic
Mechanistic drug metabolism and regulation of metabolic enzyme gene expression
Chemistry patents relevant to the medicinal chemistry field.